PROTAGONIST THERAPEUTICS,INC. (NASDAQ:PTGX) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0
PROTAGONIST THERAPEUTICS,INC. (NASDAQ:PTGX) Files An 8-K Regulation FD Disclosure

PROTAGONIST THERAPEUTICS,INC. (NASDAQ:PTGX) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Attached hereto as Exhibit99.1 is a copy of apresentationthat the Company intends to use in connection with a conference call on August6, 2018.

The information in this Current Report on Form8-K, including the attached Exhibit99.1, is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form8-K.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

99.1 Protagonist Therapeutics,Inc. Presentation dated August6, 2018


Protagonist Therapeutics, Inc Exhibit
EX-99.1 2 a18-18323_4ex99d1.htm EX-99.1 Exhibit 99.1 Dinesh V. Patel,…
To view the full exhibit click here

About PROTAGONIST THERAPEUTICS,INC. (NASDAQ:PTGX)

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn’s disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.